Patents Examined by Nizal S. Chandrakumar
  • Cannabis based therapeutic and method of use
    Patent number: 11684604
    Abstract: The present disclosure relates to cannabinoid-based therapeutics, and their use in treating pain, e.g., chronic pain. The present disclosure also relates to cannabinoid-based therapeutics, and their use in treating opioid addiction.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: June 27, 2023
    Assignee: YUZU LV LLC
    Inventor: Nicola Michael Spirtos
  • Substituted alkylphenols as HCN1 antagonists
    Patent number: 11684590
    Abstract: Provided herein are compounds (e.g., compounds of Formula (I) and Formula (II), that modulate HCN channels, intermembrane proteins that serve as nonselective voltage-gated cation channels in the plasma membranes of heart and brain cells. Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HCN-related disorders (e.g., pain) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: June 27, 2023
    Assignee: Cornell University
    Inventors: Gareth R. Tibbs, Peter A. Goldstein, Anthony A. Sauve, Rajendra Uprety, James David Warren, Jr., Rebecca L. Joyce, Dipti N. Barman
  • Methods, compositions, and kits addressing depressed mood
    Patent number: 11684647
    Abstract: A method of treating or preventing postpartum blues or depression is described, comprising administering to a subject in need thereof: an antioxidant source; a tryptophan composition comprising from 1.0 g to 5.0 g of tryptophan; and a tyrosine composition comprising from 2.0 g to 50 g of tyrosine. The antioxidant source may comprise a food or an extract derived from such a food as grapes, berries such as blueberries, citrus fruit, pomegranate, tomato, squash, carrot, sweet potato, dark green vegetables, beets, leafy vegetables, Brassica oleracea vegetables, peppers, melons, pineapples, lentils, plant oils, and/or tree nuts.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: June 27, 2023
    Assignee: CENTRE FOR ADDICTION AND MENTAL HEALTH
    Inventor: Jeffrey H. Meyer
  • Thickened organic liquid compositions with polymeric rheology modifiers
    Patent number: 11678661
    Abstract: Disclosed are thickened organic liquid compositions comprising an organic liquid and a polymeric rheology modifier wherein the polymeric rheology modifier is obtainable by co-polymerizing at least two of a bicyclic (meth)acrylate ester, an alkyl (meth)acrylate, and an aromatic vinyl monomer. Also disclosed are thickened organic liquid dispersions with suspended solids and methods of stabilizing dispersions using polymeric rheology modifiers.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: June 20, 2023
    Assignee: NOURYON CHEMICALS INTERNATIONAL B.V.
    Inventors: Shawn Zhu, John Socrates Thomaides, Andrew Richard Boracci, Anthony John Adamo, Diane Principe-Frank, Qiwei He, John M. Morales
  • Deuterated analogs of etifoxine, their derivatives and uses thereof
    Patent number: 11672805
    Abstract: This invention relates to deuterated analogs of etifoxine of Formula 1, solvates, prodrugs, and pharmaceutically acceptable salts thereof, as well as to methods for their preparation and use, and to pharmaceutical compositions. Briefly, this invention is generally directed to deuterated analogs of etifoxine as well as to methods for their preparation and use, and to pharmaceutical compositions containing the same.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: June 13, 2023
    Assignee: GABA THERAPEUTICS INC.
    Inventor: Olivier Dasse
  • Oral products with reduced irritation
    Patent number: 11672862
    Abstract: The disclosure provides products configured for oral use, the products including one or more agents adapted to or configured to reduce irritation that may be associated with release of a component from the products. Xylitol in particular may be useful as an irritation reducing agent. The disclosure further provides methods of reducing irritation associated with the release of one or more components from an oral composition or product.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: June 13, 2023
    Assignee: Nicoventures Trading Limited
    Inventors: Anthony Richard Gerardi, Dwayne William Beeson, Darrell Eugene Holton, Jr., Ronald K. Hutchens, Christopher Keller, Thomas H. Poole, Andries Don Sebastian, Frank Kelley St. Charles
  • Multi-arm polymeric alkanoate conjugates
    Patent number: 11672776
    Abstract: Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the same. Methods of treatment employing such conjugates and related uses are also provided. The conjugates are prepared with high drug loading efficiencies.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: June 13, 2023
    Assignee: Nektar Therapeutics
    Inventors: Antoni Kozlowski, Samuel P. McManus, Jennifer Riggs-Sauthier, Xiaoming Shen, Wen Zhang
  • Methods and compositions for treatment of cancer
    Patent number: 11667666
    Abstract: In an aspect, the disclosure pertains to inhibitors of ANGPTL4; synthesis methods for making disclosed compounds; pharmaceutical compositions comprising disclosed compounds; methods of treating disorders of uncontrolled cellular proliferation, e.g., a cancer; and methods of treating a disease associated with an ANGPTL4 dysfunction using disclosed compounds and pharmaceutical compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
    Type: Grant
    Filed: January 19, 2021
    Date of Patent: June 6, 2023
    Assignee: CFD RESEARCH CORPORATION
    Inventor: Anuj Singhal
  • Cannabinoid conjugate molecules
    Patent number: 11660348
    Abstract: Disclosed are conjugate molecules formed from an active agent which is linked to a cannabinoid moiety through a specified linker having ester and amide end groups. The active agent can be a COX-2 inhibitor moiety, and the cannabinoid moiety can be a cannabidiol moiety. These conjugate molecules are contemplated to potentially be effective in the treatment of medical conditions.
    Type: Grant
    Filed: November 8, 2022
    Date of Patent: May 30, 2023
    Assignee: AKOS BIOSCIENCES, INC.
    Inventors: Paul M. Hershberger, Yinghui Liu, Kirk William Hering, James Bernard Kramer, Ramanathan S. Lalgudi
  • Self-emulsifying anhydrous intradermal depot gel
    Patent number: 11660284
    Abstract: The present invention relates to compositions and methods to solubilize poorly water-soluble medicaments using a self-emulsifying, anhydrous gel (SEAG), which then forms an intradermal depot when absorbed. The gel preferably comprises a mixture of propylene glycol, glycerin, ethoxy diglycol, hydroxypropylcellulose, butylated hydroxytoluene, caprylic acid triglyceride and edetate disodium, and may further include an oral-based, bioadhesive paste, which allows the gel to adhere mucosally. The SEAG may further contain a solubilizer such as Kolliphor HS15.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: May 30, 2023
    Assignee: MEDPHARM HOLDINGS, LLC
    Inventor: Scott Karolchyk
  • Preventing thermal trauma by pre-treatment with Icilin
    Patent number: 11660298
    Abstract: The present invention comprises a method of use of Icilin as a pre-treatment to mitigate the negative effects of extreme thermal trauma to skin tissue on a cellular level. Pre-treatment with Icilin prior to exposure to a thermal trauma event is shown to improve cellular viability, reduce pro-inflammatory cytokine levels, and reduce Reactive Oxygen Species (ROS) levels. The treatment is designed to be administered in small doses at concentrations of 0.0002-0.02 nM dissolved in an aprotic polar solvent such as dimethyl sulfoxide.
    Type: Grant
    Filed: August 1, 2020
    Date of Patent: May 30, 2023
    Inventor: Kevin Chew
  • Tryptamine compositions for enhancing neurite outgrowth
    Patent number: 11660305
    Abstract: Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: May 30, 2023
    Assignee: TURTLE BEAR HOLDINGS, LLC
    Inventor: Paul Edward Stamets
  • Oral cannabinoid pharmaceutical compositions and methods of treating sleep disorders
    Patent number: 11654130
    Abstract: Oral cannabinoid pharmaceutical compositions and methods of treating sleep disorders using the oral cannabinoid pharmaceutical compositions are described.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: May 23, 2023
    Assignee: CURIO IP, LLC
    Inventors: Edward M. Rudnic, Michael Bronfein
  • Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
    Patent number: 11648245
    Abstract: The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators, including their use for treating amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: May 16, 2023
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Hazel Hunt, Tony Johnson, Nicholas Ray, Iain Walters
  • Borate salts, polymers and composites
    Patent number: 11649358
    Abstract: Described herein are borate salts useful as additives, binders, and electrolyte salts for solid state lithium ion batteries. In particular, the borate salts of Formula (I), Formula (II) and Formula (III) as described herein: can be polymerized, or can be bound to an existing polymer, to provide polymeric binders for ceramic solid state electrolytes that are themselves capable of ion transport independent of the ceramic.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: May 16, 2023
    Assignee: UCHICAGO ARGONNE, LLC
    Inventors: Chen Liao, Trevor L. Dzwiniel, Kewel Liu
  • Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
    Patent number: 11642344
    Abstract: The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor: (Compound A) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the composition comprises a therapeutically effective amount of said Compound A CETP inhibitor.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: May 9, 2023
    Assignee: NewAmsterdam Pharma B.V.
    Inventors: John Ford, Patrick Round, John Kastelein, Atsuhiro Kawaguchi, Koichi Tomiyasu, Kozo Oka
  • Use of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] for the treatment of cancer
    Patent number: 11633380
    Abstract: IT-139, sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)], is an intravenously administered small molecule compound. In preclinical anti-tumor and mechanism of action studies, IT-139 showed activity against a broad range of tumor types, including those which are resistant to standard anti-cancer agents (e.g., platinums, vinca alkaloids, taxanes, anthracyclines). This activity is believed to arise from IT-139's novel mechanism of action that targets the GRP78 pathway. It was found that up-regulation of GRP78 is a key cancer cell survival pathway. Downregulation of GRP78 using IT-139 removes this resistance pathway allowing for chemotherapy and immuno-oncology agents to be more effective in treating cancer.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: April 25, 2023
    Assignee: BOLD THERAPEUTICS, INC.
    Inventors: Suzanne Bakewell, Jyothi Sethuraman
  • Organic electro-optic chromophores
    Patent number: 11634429
    Abstract: Chromophores with large hyperpolarizabilities, films with electro-optic activity comprising the chromophores, and electro-optic devices comprising the chromophores are disclosed.
    Type: Grant
    Filed: April 4, 2022
    Date of Patent: April 25, 2023
    Assignee: University of Washington
    Inventors: Delwin Elder, Lewis Johnson, Bruce Robinson, Huajun Xu
  • Co-crystals of boscalid and triazoles
    Patent number: 11632956
    Abstract: The present invention relates to co-crystals of boscalid and a triazole fungicide.
    Type: Grant
    Filed: December 15, 2018
    Date of Patent: April 25, 2023
    Assignee: UPL LTD
    Inventors: Rakesh Bhulabhai Patel, Satish Ekanath Bhoge, Jaidev Rajnikant Shroff, Vikram Rajnikant Shroff
  • Solid forms comprising an oxime ether compound, compositions and methods of use thereof
    Patent number: 11629124
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: April 18, 2023
    Assignee: NOVARTIS AG
    Inventors: Lianfeng Huang, Daozhong Zou